Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/07/20
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality TherapyGlobeNewsWire • 02/14/20
Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian CancerGlobeNewsWire • 02/11/20
Myriad Genetics, Inc. (MYGN) CEO Bryan Riggsbee on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/07/20
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian CancerGlobeNewsWire • 01/22/20
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate CancerGlobeNewsWire • 01/21/20
Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad OncologyGlobeNewsWire • 01/14/20
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED StudyGlobeNewsWire • 01/06/20
This Genetic-Testing Stock Popped, Then Slipped, On Its FDA ApprovalInvestors Business Daily • 12/30/19
Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancerMarket Watch • 12/30/19
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic CancerGlobeNewsWire • 12/30/19